GT Biopharma Files Additional Proxy Materials
Ticker: GTBP · Form: DEFA14A · Filed: Jun 17, 2024 · CIK: 109657
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, pharmaceutical
TL;DR
GT Biopharma dropped more proxy docs, check 'em.
AI Summary
GT Biopharma, Inc. filed a Definitive Additional Materials proxy statement on June 17, 2024. The filing concerns matters related to the company's proxy statement, indicating it's providing supplementary information to shareholders. The company, previously known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides shareholders with updated or supplementary information regarding matters to be voted on at a shareholder meeting, impacting corporate governance and strategic decisions.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement supplement and does not contain new financial information or significant corporate actions that would inherently increase risk.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- 20240617 (date) — Filing Date
FAQ
What type of filing is GT Biopharma submitting?
GT Biopharma, Inc. is submitting a Definitive Additional Materials proxy statement.
When was this filing made?
The filing was made on June 17, 2024.
What is GT Biopharma's industry?
GT Biopharma, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Has GT Biopharma operated under different names previously?
Yes, GT Biopharma, Inc. was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Where is GT Biopharma headquartered?
GT Biopharma, Inc.'s business and mail address is 8000 MARINA BLVD, SUITE 100, BRISBANE, CA 94005.
Filing Stats: 288 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-06-17 16:26:23
Filing Documents
- formdefa14a.htm (DEFA14A) — 18KB
- formdefa14a_001.jpg (GRAPHIC) — 2KB
- 0001493152-24-024128.txt ( ) — 23KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 GT BIOPHARMA, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No Fee Required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. On June 17, 2024, GT Biopharma, Inc. (the “ Company ”) issued the following letter to its stockholders holding 100 or more shares of the Company’s common stock. 8000 Marina Boulevard Suite 100 Brisbane, CA 94005 www.gtbiopharma.com *** YOUR VOTE IS IMPORTANT*** June 17, 2024 Dear GT Biopharma Stockholder: The Annual Meeting of Stockholders is soon approaching and is scheduled to be held on June 25 , 2024 at 9:00 AM Pacific Time. We are sending this reminder notice because according to records from the vote processor your shares are unvoted. Voting is quick and easy. We urge you promptly to submit your vote by internet or telephone by using the control number located on the enclosed voting instruction form. Regardless of the number of shares you own; your vote is very important. If you have any questions or need assistance voting your shares, please contact our proxy solicitor, Saratoga Proxy Consulting at (888) 368-0379 or (212) 257-1311. Thank you for your continued support, GT Biopharma